‘Chemo mouth’, otherwise known as oral mucositis, has emerged as the most significant adverse event in oncology, according to a National Comprehensive Cancer Network task force.
Eli Lilly may be on the brink of reshaping the pharma landscape, with its treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Cytiva has announced the launch of its Xcellerex magnetic mixer – a single-use mixing system designed to address challenges faced by customers engaged in large-scale mAb, vaccine and genomic medicine manufacturing processes.
Pfizer’s drug Velsipity (etrasimod), for the treatment of moderate to severe ulcerative colitis (UC), recently received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
In the fast-paced domain of pharmaceutical contract development and manufacturing organizations (CDMOs), Selkirk Pharma believes it stands out as a beacon of innovation and reliability.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
Patrick Thiaville is chief scientific officer of Exothera Nucleic Acids, a viral vector CDMO (contract manufacturing and development organization) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines...
Elisa Cascade is the chief product officer at Advarra and is responsible for driving the clinical research company's technology product vision and management. We had a fascinating and inspiring conversation with her - touching on imposter syndrome,...
Great Ormond Street Hospital (GOSH) has announced its new plan to ‘revolutionise’ how children living with rare diseases can gain access to cutting-edge gene therapy.
Pfizer has been accused of ‘bringing discredit’ on the pharma industry after senior employees promoted its ‘unlicensed’ COVID-19 vaccine through social media at the height of the pandemic.
Recurring urinary tract infections (UTIs) can be prevented for up to nine years with a simple oral spray vaccine, a ‘breakthrough’ British trial has shown.
In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.
Last week (April 5), the American Association for Cancer Research (AACR) welcomed the industry to the San Diego Convention Center for the AACR Annual Meeting 2024.
Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.
Cartherics has entered a collaborative research agreement with TiCARos, to assess the company's proprietary CLIP-CAR technology in its induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells.
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
Consumer health company Haleon has published a first-of-its kind study highlighting the significant positive impact that its nasal decongestant Otrivin can have on patients’ quality of life.
AstraZeneca CEO Sir Pascal Soriot has been awarded one of the highest honours by science institution SCI for his role in ‘accelerating scientific innovation’ and for leading the company’s global COVID-19 vaccination programme.
“When you have people who like what they do and believe they’re having an impact, you can do anything – more than any project or investment. Prioritise your teams and people because they’re your biggest asset.”
Curve Therapeutics, a biotech pioneering an intracellular screening platform addressing complex and challenging disease targets, has announced the publication of an article in the Journal of the American Chemical Society (JACS).
This week, the pharma industry will descend on Pennsylvania Convention Center for Reuters Pharma USA, North America’s largest cross-functional pharma gathering.
The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.
Since Roche's Zelboraf (vemurafenib)gained FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma.
With the pharma and healthcare landscape increasingly being shaped by artificial intelligence (AI), the US Food and Drug Administration (FDA) has taken proactive steps to outline a comprehensive strategy for regulating AI in medical products.
Within the current treatments of Parkinson’s disease (PD) there is an unmet need for addressing the loss of dopaminergic neurons and non-motor symptoms.
Biopharma company Clene has published ‘impactful’ new research into CNM-Au8, its investigational drug in development for the treatment of neurodegenerative diseases.
A huge €128 million Series B2 round by German startup Tubulis indicates that the field of antibody-drug conjugates (ADCs) in oncology continues to capture investor imaginations.
Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC).
Austian start-up Sarcura has secured a €1.7 million grant to help the company develop a ‘miniaturized and autonomous’ cell therapy manufacturing platform using deep tech.
One of the most challenging aspects of the COVID-19 pandemic was not being able to assess how individual patients would respond to the virus and how severe their symptoms would be.
Despite previously calling the UK a ‘very unattractive’ place to do business, AstraZeneca CEO Pascal Soriot is injecting £650 million into the UK life sciences industry.
Swedish-based company Empros Pharma has announced positive topline data from its phase 2b trial investigating EMP16, an oral therapy for the treatment of obesity.
Biotech company Transgene, IT solutions provider NEC, and biomedical software company BostonGene have expanded their collaboration for the phase 1/2 trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.
Hayley Crowe is executive vice president and general manager of Ecolab’s Global Life Sciences sector, comprised of Ecolab’s Purolite and pharma / personal care businesses. We sat down with Hayley to discuss how adversity inspired her determination to...
Form Bio and Ginkgo Bioworkshave joined forces in what they call a groundbreaking partnership aimed at advancing AAV gene therapy design and development.
Terumo Blood and Cell Technologies is working to improve treatment for pregnant sickle cell sufferers, publishing first-of-its-kind international consensus recommendations for these patients.
Neurogene, a clinical-stage company developing genetic medicines, is expanding its ongoing phase 1/2 clinical trial investigating NGN-401 as a treatment for female pediatric patients with Rett Syndrome.
SolasCure is moving forward with its maggot-derived wound gel, after publishing the results of its recent phase 2 clinical trial in a leading wound care journal.
California-based biotech company Metabolomycs has released a new study demonstrating how pancreatic cancer could be diagnosed earlier with a blood test.